News
Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS
5+ hour, 38+ min ago (363+ words) PREVAiLS is a pivotal, global, 500-participant Phase 3 study to evaluate efficacy and safety of pridopidine, an investigational drug, in slowing ALS progression (ALSFRS-R) in early, rapidly progressive participants The design of the potentially registrational pivotal Phase 3 study is informed by,…...
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
8+ hour, 47+ min ago (125+ words) Enrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026 Enrollment on-track in Study 306, the first-ever Phase 2/3 trial of an oral treatment specifically for female pattern hair loss Mark…...
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
3+ hour, 54+ min ago (239+ words) The IV Verify system includes a printer, labels and patented ink-free technology and is designed to support: The introduction of the IV Verify Line Labeling System reflects Baxter's ongoing commitment to helping advance safer infusion practices through practical, clinician-focused innovation....
Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
8+ hour, 47+ min ago (461+ words) OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrate OLN324 achieves faster, greater, and more durable reductions in wAMD pigment…...
LIB Therapeutics Announces Results from Presentations on LEROCHOL® at 2026 American College of Cardiology meeting in New Orleans March 28-29, 2026
5+ hour, 22+ min ago (277+ words) The 72-week open-label study, which over 90% of participants completed, provides further information on lerodalcibep's longer term safety and tolerability, patient adherence, and robust and sustained reductions in LDL-C and other lipids and lipoproteins," commented Dr David Kallend, Chief Medical Officer…...
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
5+ hour, 30+ min ago (548+ words) - REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week…...
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
7+ hour, 13+ min ago (577+ words) Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU" for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan'BioSpace Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU" for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan…...
Google News
6+ hour, 57+ min ago (21+ words) New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management'BioSpace...
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
6+ hour, 57+ min ago (349+ words) The Phase 3 CORALreef AddOn trial compared the efficacy and safety of enlicitide to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe Enlicitide has the potential to be the first approved oral PCSK9 inhibitor designed to help address critical unmet needs for…...
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform
5+ hour, 40+ min ago (392+ words) Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform'BioSpace Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and…...